AAV serotype influences gene transfer in corneal stroma in vivo
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
This study evaluated the cellular tropism and relative transduction efficiency of three AAV serotypes, AAV6, AAV8 and AAV9, for corneal gene delivery using mouse cornea in vivo and donor human cornea ex vivo. The AAV6, AAV8 and AAV9 serotypes having AAV2 plasmid encoding for alkaline phosphatase (AP) gene were generated by transfecting HEK293 cell line with pHelper, pARAP4 and pRep/Cap plasmids. Viral vectors (109 vg/μl) were topically applied onto mouse cornea in vivo and human cornea ex vivo after removing the epithelium. Human corneas were processed for transgene delivery at day 5 after viral vector application. Mouse corneas were harvested at 4, 14 and 30 days after vector application for AP staining. Transduction efficiency was calculated by quantifying pixels of AP-stained area using Image J software and also confirmed by functional AP enzyme activity in the corneal lysates. Cellular toxicity of the three AAV serotypes was tested with TUNEL assay. Inflammatory response was detected by immunostaining for CD11b and F4/80. All three AAV serotypes successfully transduced mouse and human corneas. The order of transduction efficiency was AAV9>AAV8>AAV6. The transduction efficiency of AAV9 was 1.1–1.4 fold higher (p>0.05) as compared to AAV8 and 3.5–5.5 fold higher (p<0.01) as compared to AAV6. The level of transgene expression for all the three serotypes was greater at 14 days compared to 4 days and this high level of transgene expression was maintained up to the tested time point of 30 days. Corneas exposed to any of the three AAV serotypes did not show significant TUNEL positive cells or any inflammatory response as tested by CD11b or F4/80 staining suggesting that tested AAV serotypes do not induce cell death or inflammation and are safe for corneal gene therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924 · cited 1×
“Improved visual function in patients of Leber’s congenital amaurosis treated with gene therapy affirms its clinical potential for ocular diseases (Bainbridge et al., 2008; Maguire et al., 2008).”
New recombinant serotypes of AAV vectors
Gao, G., Vandenberghe, L., & Wilson, J. (2005) · Current Gene Therapy · doi:10.2174/1566523054065057 · Cited by 487
Recombinant Adeno-Associated Virus Serotype 9 Leads to Preferential Cardiac Transduction In Vivo
Pacak, C. A., Mah, C. S., Thattaliyath, B. D., Conlon, T. J., Lewis, M. A., Cloutier, D. E., Zolotukhin, I., Tarantal, A. F., & Byrne, B. J. (2006) · Circulation Research · doi:10.1161/01.res.0000237661.18885.f6 · Cited by 406
Tailoring the AAV vector capsid for gene therapy
Vandenberghe, L. H., Wilson, J. M., & Gao, G. (2009) · Gene Therapy · doi:10.1038/gt.2008.170 · Cited by 155
Howard, D. B., Powers, K., Wang, Y., & Harvey, B. K. (2008) · Virology · doi:10.1016/j.virol.2007.10.007 · Cited by 149 · cited 2×
“Among the 7 tested serotypes, Bish et al showed AAV9 as the most efficient for gene delivery in rodent heart whereas it was the least effective serotype for transducing neurons (Howard et al., 2008).”
Ghosh, A., Yue, Y., & Duan, D. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.835 · Cited by 69 · cited 2×
“AAV vectors were generated using adenovirus free system following previously published protocol (Ghosh et al., 2006).”
Self-citation
Cited by
A review of keratoconus: Diagnosis, pathophysiology, and genetics
Mas Tur, V., MacGregor, C., Jayaswal, R., O'Brart, D., & Maycock, N. (2017) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2017.06.009 · Cited by 439
Structural insight into the unique properties of adeno-associated virus serotype 9
DiMattia, M. A., Nam, H.-J., Van Vliet, K., Mitchell, M., Bennett, A., Gurda, B. L., McKenna, R., Olson, N. H., Sinkovits, R. S., Potter, M., et al. (2012) · Journal of Virology · doi:10.1128/jvi.07232-11 · Cited by 219
Immunology of AAV-Mediated Gene Transfer in the Eye
Willett, K., & Bennett, J. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00261 · Cited by 105
“For example, lacrimal gland injection (6), topical eye drops (7, 8), intra-stromal corneal injection (9), and intra-cameral injection (10) provide access to the ocular surface, cornea, and anterior chamber which are implicated in dry eye disease, corneal dystrophies, and glaucoma.”
BackgroundTreatment of ocular disorders by gene therapy
Solinís, M. Á., del Pozo-Rodríguez, A., Apaolaza, P. S., & Rodríguez-Gascón, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.12.022 · Cited by 88
Serotype survey of AAV gene delivery via subconjunctival injection in mice
Song, L., Llanga, T., Conatser, L. M., Zaric, V., Gilger, B. C., & Hirsch, M. L. (2018) · Gene Therapy · doi:10.1038/s41434-018-0035-6 · Cited by 50
“dement or intrastromal injections [13], little is known about”
Metadata
- Authors
- Sharma, A., Tovey, J. C. K., Ghosh, A., & Mohan, R. R.
- Venue
- Experimental Eye Research
- Publisher
- Elsevier BV
- Published
- 2010-09
- Volume
- 91
- Issue
- 3
- Pages
- 440-448
- ISSN
- 0014-4835 (ISSN-L)
- OpenAlex
- W1989136633
- Cited by
- 51
- References
- 7
- FWCI
- 3.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.